News
Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback